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internal compartments. Colocalization of HCP1 with en-
dosomal markers such as Rab 5 or Rab 11 or with other
markers may help to characterize the internal compart-
ments in which HCP1 resides.
Once the intracellular compartments to which HCP1
relocates in iron-rich animals have been characterized,
the larger question will be how is such trafficking regu-
lated? In iron-rich animals, the iron transporter ferro-
portin in the basolateral membrane of gut epithelial
cells moves to an intracellular location (the lysosomes)
after binding to hepcidin, a peptide hormone synthe-
sized in the liver (Nemeth et al., 2004). However, when
released from the liver into the bloodstream, hepcidin
most likely cannot directly access the apical membrane
or internal compartments of gut epithelial cells, sug-
gesting a more complicated mechanism for regulation
of HCP1 trafficking. Perhaps the time has come when
protein trafficking researchers will recognize that identi-
fication of targeting motifs, intracellular compartments,
and the regulation of iron and heme transporters in po-
larized epithelial cells represents an important frontier.
Similarly, metallobiology researchers should pay atten-
tion to the changes in subcellular locations of transpor-
ters such as HCP1 that accompany alterations in physi-
ological stimuli and should attempt to understand how
this movement of transporters is regulated.
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Osteoblasts Clock in
for Their Day Job
The proteins encoded by clock genes regulate circa-
dian variations of various cellular functions. In this
issue of Cell, Fu, Karsenty, and colleagues (Fu et al.,
2005) demonstrate that clock genes control the prolif-
eration of osteoblasts, the cells that promote growth
of bone. These findings indicate that the homeostatic
regulation of bone mass is subject to circadian control.
Bones are constantly being remodeled by the opposing
actions of bone-promoting cells called osteoblasts and
bone-degrading cells called osteoclasts (Rodan and
Martin, 2000). Osteoclasts degrade the existing bone
matrix, whereas osteoblasts synthesize it anew. Through
this process, bone mass is kept constant in healthy
adult organisms. Bone remodeling is controlled by a
complex set of factors including systemic factors (such
as steroid hormones, PTH, and leptin) and those
secreted by osteoblasts that regulate osteoclast differ-
entiation (such as RANK ligand and Osteoprotegerin, a
soluble decoy receptor for the RANK ligand). Synthesis
of new bone by osteoblasts is also controlled by sev-
eral cell-specific transcription factors. The work of Fu,
Karsenty, and colleagues (Fu et al., 2005) described in
this issue of Cell indicates that an important, new regu-
lator of bone remodeling is the circadian cycle.
Many physiological functions in metazoan organisms
are regulated by circadian clocks (Schibler and Sas-
sone-Corsi, 2002; Fu and Lee, 2003). In mammals, cir-
cadian variations in peripheral tissues are largely syn-
chronized by the suprachiasmatic nucleus of the
hypothalamus. Genes that control these diurnal varia-
tions are generically called clock genes. Fu et al. (2005)
hypothesize that clock genes might control bone re-
modeling. Previous work has in fact shown that expres-
sion of two major extracellular matrix proteins in bone,
type I collagen and osteocalcin, display circadian varia-
tion (Simmons and Nichols, 1966; Gundberg et al., 1985).
In the new work, Fu and coworkers (2005) demon-
strate that several clock genes are indeed expressed
in osteoblasts and, not surprisingly, display a circadian
pattern of expression. Their work focuses principally on
two of these genes, Per1 and Per2. To begin testing
their hypothesis, they asked whether the homeostasis
of bone remodeling was altered in Per-deficient mice.
They found that mice deficient in both Per1 and Per2
have markedly increased bone mass, which they dem-
onstrated was due to enhanced osteoblast proliferation
and not inhibition of bone degradation. The authors
noted that this high bone mass phenotype is similar to
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652that seen in two other strains of mutant mice—animals
deficient in leptin and those deficient in the β2-adrener-
gic receptor—previously characterized by the Karsenty
group (Ducy et al., 2000; Takeda et al., 2002). In these
studies, Karsenty and colleagues made the important
observation that the neuropeptide leptin controls bone
mass by binding to leptin receptors expressed by hypo-
thalamic neurons leading to inhibition of osteoblast
proliferation. They speculated that clock genes might
either control leptin expression or mediate the effects
of leptin in osteoblasts. Leptin signaling in the hypo-
thalamus is relayed by the sympathetic nervous system
through β2-adrenergic receptors expressed by osteo-
blasts. Importantly, the mediators of leptin’s regulation
of bone mass do not affect leptin’s other activities such
as the control of appetite and gonadal functions.
Evidence from their new work argues against a major
role of the Per clock genes in the control of leptin ex-
pression because levels of free leptin are similar in wild-
type and Per-deficient mice. Instead, the results are
consistent with the hypothesis that leptin signaling
might control Per expression in osteoblasts. In agree-
ment with this notion, the high bone mass phenotype
persists when the Per2 gene is specifically inactivated
in osteoblasts of a Per1-deficient mouse. Two addi-
tional sets of experiments also support this view. First,
treatment of osteoblasts with the sympathomimetic
substance isoproterenol increased expression of Per1,
Per2, and another clock gene. Second, intracerebro-
ventricular infusion of leptin, which decreases bone
mass in wild-type mice, did not produce this effect in
Per-deficient mice, but instead had the paradoxical ef-
fect of increasing bone mass.
The latter observation prompted Fu et al. (2005) to
examine the mechanisms for the increased proliferation
of osteoblasts seen in Per-deficient mice. They found
that expression of the cell cycle regulatory genes cyclin
D1 and cyclin E is upregulated in osteoblasts from Per-
deficient mice. Similarly, the expression of c-Myc and
of several AP1 genes encoding the transcription factors
c-fos, JunB, and c-Jun is also upregulated in bone.
These results provide a plausible molecular mechanism
for the increase in osteoblast proliferation in Per–defi-
cient animals and suggests that the products of the Per
genes inhibit osteoblast proliferation by blocking ex-
pression of genes that promote proliferation. Moreover,
Fu et al. (2005) demonstrate from transfection experi-
ments that clock proteins block the c-Myc promoter.
When they treated osteoblasts from Per-deficient mu-
tant mice with isoproterenol, to mimic the action of lep-
tin in vivo, there was no block in the expression of
cyclins D1 and E as was the case with wild-type animals.
Isoproterenol increased the expression of c-fos and
other AP1 genes in wild-type osteoblasts, and this in-
crease was even greater in osteoblasts from Permutant
animals. These findings suggest that although activa-
tion of β2-adrenergic receptors boosts the expression
of the AP1 gene, Per proteins inhibit this effect. Previ-
ous genetic experiments by others strongly suggest
that AP1 increases osteoblast proliferation (Kenner et
al., 2004). Thus, leptin signaling through β2-adrenergic
receptors, which mediates the effects of leptin in osteo-
blasts, appears to have two antagonistic effects. The first
is the inhibition of osteoblast proliferation and c-Myc
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(xpression through the action of clock proteins, and
he second is the stimulation of osteoblast proliferation
hrough the action of AP1 proteins. It is the stimulation
f AP1 expression by leptin signaling via β2-adrenergic
eceptors that is likely to account for the further in-
rease in bone mass after intracerebroventricular infu-
ion of leptin in Per-deficient mice.
The model that emerges from the results of Fu et al.
2005) suggests that signaling by β2-adrenergic receptors
irst activates the transcription factor CREB. CREB in turn
timulates expression of clock genes, which inhibit prolif-
ration of osteoblasts, and AP1 genes, which stimulate
roliferation of osteoblasts. The Fu et al. (2005) work pro-
ides evidence that the inhibition of osteoblast prolifera-
ion by clock proteins is the dominant effect.
The Karsenty group has also recently reported that
eptin signaling increases expression of RANK ligand in
steoblasts resulting in a boost in the differentiation of
steoclasts leading to enhanced degradation of bone.
he increased expression of RANK ligand by osteo-
lasts is mediated by signaling through the β2-adrener-
ic receptor, but its effect is also counterbalanced by
he leptin-induced expression of a hypothalamic neuro-
eptide called Cart, which inhibits the expression of
ANK ligand in osteoblasts (Elefteriou et al., 2005). Per-
aps the decrease in bone mass produced by leptin
ignaling is such a critical function that both the inhibi-
ion of osteoblast proliferation and the increased deg-
adation of bone by osteoclasts need to be buffered
nd counterbalanced by opposing mechanisms.
A number of other questions are raised by the in-
ightful study of Fu et al. (2005). For instance, are the
ircadian variations in leptin levels and in Per expres-
ion synchronized? And, if Per gene expression in osteo-
lasts is regulated autonomously, does leptin enhance
he physiological oscillations in Per gene expression?
lso, is AP1 gene expression in osteoblasts subject to
ircadian variation that operates independently of cir-
adian variations controlled by clock proteins? Finally,
hat is the physiological significance for bone tissue of
nhibiting osteoblast proliferation during a defined time
eriod each day? One might speculate that such a time
eriod would allow osteoblasts to focus on other func-
ions such as the expression of their genetic program.
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